TY - JOUR
T1 - Feasibility of intravenous administration of landiolol hydrochloride for multislice computed tomography coronary angiography - Initial experience
AU - Isobe, Satoshi
AU - Sato, Kimihide
AU - Sugiura, Kaichiro
AU - Mimura, Takeo
AU - Kobayashi, Mikiko
AU - Meno, Chizuka
AU - Kato, Makoto
AU - Ishii, Hideki
AU - Murohara, Toyoaki
PY - 2008
Y1 - 2008
N2 - Background: The feasibility of using landiolol hydrochloride in multislice computed tomography (MSCT) coronary angiography (CAG) was investigated in the present study. Methods and Results: Landiolol hydrochloride was continuously administered intravenously to 145 patients before starting MSCT CAG. Hemodynamic changes [blood pressure (BP), heart rate (HR)], adverse effects, image quality using a 5-point scale, and accuracy of detecting significant stenoses (≥50% reduction in lumen diameter) were evaluated. HR was significantly reduced during injection, and quickly recovered after cessation of administration, of landiolol hydrochloride. Neither significant changes in BP nor adverse effects occurred. Among visible segments, 1,869 (94%) displayed an excellent (83%) or good (11%) image quality. Diagnostic accuracy was evaluated in 39 of 145 patients who underwent invasive CAG within 3 weeks after MSCT. The sensitivity, specificity, positive predictive value, and negative predictive value of MSCT CAG for detection of significant stenoses in assessable segments were excellent (per artery: 94%, 98%, 92%, and 100%; per segment: 92%, 98%, 94%, and 96%, respectively). Conclusions: Intravenous administration of landiolol hydrochloride reduces HR without a significant reduction in BP, which enables favorable image quality and diagnostic accuracy without adverse effects, making this agent feasible as a premedication for MSCT CAG.
AB - Background: The feasibility of using landiolol hydrochloride in multislice computed tomography (MSCT) coronary angiography (CAG) was investigated in the present study. Methods and Results: Landiolol hydrochloride was continuously administered intravenously to 145 patients before starting MSCT CAG. Hemodynamic changes [blood pressure (BP), heart rate (HR)], adverse effects, image quality using a 5-point scale, and accuracy of detecting significant stenoses (≥50% reduction in lumen diameter) were evaluated. HR was significantly reduced during injection, and quickly recovered after cessation of administration, of landiolol hydrochloride. Neither significant changes in BP nor adverse effects occurred. Among visible segments, 1,869 (94%) displayed an excellent (83%) or good (11%) image quality. Diagnostic accuracy was evaluated in 39 of 145 patients who underwent invasive CAG within 3 weeks after MSCT. The sensitivity, specificity, positive predictive value, and negative predictive value of MSCT CAG for detection of significant stenoses in assessable segments were excellent (per artery: 94%, 98%, 92%, and 100%; per segment: 92%, 98%, 94%, and 96%, respectively). Conclusions: Intravenous administration of landiolol hydrochloride reduces HR without a significant reduction in BP, which enables favorable image quality and diagnostic accuracy without adverse effects, making this agent feasible as a premedication for MSCT CAG.
UR - http://www.scopus.com/inward/record.url?scp=55449116683&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=55449116683&partnerID=8YFLogxK
U2 - 10.1253/circj.CJ-08-0336
DO - 10.1253/circj.CJ-08-0336
M3 - Article
C2 - 18827370
AN - SCOPUS:55449116683
SN - 1346-9843
VL - 72
SP - 1814
EP - 1820
JO - Circulation Journal
JF - Circulation Journal
IS - 11
ER -